Skip to main navigation
Skip to search
Skip to main content
UNT Health Home
Search content at UNT Health
Home
Research units
Profiles
Publications
Sponsored Projects
Core Facilities
Current state of Alzheimer’s fluid biomarkers
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current state of Alzheimer’s fluid biomarkers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adverse Reactions
20%
Alpha-synuclein (α-syn)
20%
Alzheimer
100%
Alzheimer's Disease
80%
Alzheimer's Disease Biomarkers
20%
Alzheimer's Disease Diagnosis
20%
Alzheimer's Disease Pathology
20%
Alzheimer's Disease Treatment
20%
Cerebrospinal Fluid
20%
Cerebrospinal Fluid Biomarkers
20%
Clinical Trials
40%
Context of Use
20%
Diagnostic Utility
20%
Disease Pathophysiology
20%
Disease States
20%
Disease-modifying Therapy
20%
Dose Optimization
20%
Drug Development
20%
Drug Development Program
20%
Drug Response Monitoring
20%
Effective Compounds
20%
Ferritin
20%
Fluid Biomarkers
100%
Heterogeneous Pathophysiology
20%
IP-10
20%
Living with
20%
Mechanism of Action
20%
Monitoring Efficacy
20%
Neurofilament Light (NF-L)
20%
Neurogranin
20%
Pathogenic Mechanism
20%
Patient Selection
20%
Personalized Medicine
20%
Phosphorylated tau
20%
Prognosis Assessment
20%
Progressive Neurodegeneration
20%
SNAP-25
20%
Sporadic Alzheimer's Disease
20%
Subject Selection
20%
Synaptotagmin
20%
TAR DNA-binding Protein 43 (TDP-43)
20%
Total tau
20%
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
20%
VILIP-1
20%
YKL-40
20%
β-site APP-cleaving Enzyme 1 (BACE1)
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Drug Development
100%
Drug Response
50%
Ferritin
50%
Neurofilament Light
50%
Neurogranin
50%
Synaptotagmin
50%
Synuclein
50%
Tau
100%
Transactive Response Dna Binding Protein-43
50%
TREM2
50%
Medicine and Dentistry
Adverse Event
12%
Alzheimer's Disease
87%
Alzheimer's Disease Biomarkers
12%
Biological Marker
100%
Cerebrospinal Fluid
25%
Clinical Trial
25%
Combination Therapy
12%
Degenerative Disease
12%
Disease Modifying Therapy
12%
Diseases
12%
Drug Response
12%
Ferritin
12%
Neurogranin
12%
Pathophysiology
25%
Patient Selection
12%
Personalized Medicine
12%
Synaptosomal Associated Protein 25
12%
Synaptotagmin
12%
Synuclein
12%
Tau
25%
Transactive Response Dna Binding Protein-43
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Alzheimer's Disease
88%
Biological Marker
100%
Clinical Trial
22%
Degenerative Disease
11%
Diseases
22%
Drug Development
22%
Ferritin
11%
Neurogranin
11%
Pathophysiology
22%
Synaptosomal Associated Protein 25
11%
Synaptotagmin
11%
Synuclein
11%
Material Science
Ferritin
50%
Transactive Response Dna Binding Protein-43
50%